Australian Public Assessment Report Reslizumab
A program supporting CINQAIR® (reslizumab) Injection patients
Dosing and Administration
Predicting Responders to Reslizumab after 16 Weeks of Treatment Using an Algorithm Derived from Clinical Studies of Patients wit
These highlights do not include all the information needed to use CINQAIR safely and effectively. See full prescribing information for CINQAIR.CINQAIR® (reslizumab) injection, for intravenous useInitial U.S. Approval: 2016
Reslizumab Prices, Coupons & Savings Tips - GoodRx
NICE changes mind and backs new drug for severe asthma | Nursing Times
Reslizumab | Teva UK
Israeli Pharma gets FDA Approval for Asthma Antibody
Teva filled Biologics License Application for reslizumab Archives • NCK Pharma
TA479 Review decision paper
Cinqair Reslizumab Injection
Cinqair (reslizumab) Injection for treatment of Severe Asthma and an Eosinophilic Phenotype - Clinical Trials Arena
Older Patients with Asthma Do Well with Reslizumab | RT
Rx Item-Cinqair (Reslizumab) 10Mg/Ml Inj Sinle Use Vial 10Ml By Teva Respiratory
Teva Announces EMA Validation of Reslizumab Marketing Authorization Application
Discount helps NICE flip-flop on Teva's severe asthma contender, Cinqair | Fierce Pharma
Cinqair (Reslizumab) 100mg/10mL Injection – Apothera
Teva files MAA for asthma treatment reslizumab
Medication Detail
Teva-Handok wins approval for anti-asthma injection < Pharma < Article - KBR
CINQAERO (reslizumab) de Teva ya está disponible en España para el asma grave no controlada | IM Farmacias
